Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma - Report - MDSpire

Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

  • By

  • Zijuan Liu

  • Yating Yan

  • Caihong Jiang

  • June 16, 2026

  • 0 min

Share

Clinical Report: The Efficacy of Tislelizumab and Bevacizumab in Managing Primary Malignant Pericardial Mesothelioma

Overview

This case study reports on a 50-year-old female patient with primary malignant pericardial mesothelioma (PMPM) who was treated with tislelizumab and bevacizumab after experiencing severe bone marrow suppression from prior chemotherapy. The patient achieved stable disease and symptom relief over a treatment period of 29.4 months.

Background

Remove implications about the need for innovative strategies without attribution.

Data Highlights

No numerical or trial data presented in the article.

Key Findings

  • The patient experienced grade IV bone marrow suppression following pemetrexed and platinum-based chemotherapy.
  • Treatment with tislelizumab and bevacizumab resulted in significant symptom relief and stable disease over 29.4 months.
  • Imaging assessments indicated no progression of the primary tumor lesion during the treatment period.
  • Adverse reactions were limited to grade II bone marrow suppression and mild skin issues, without severe complications.
  • The patient's survival of 2.76 years exceeds the typical survival rates reported for PMPM.

Clinical Implications

This case suggests that tislelizumab combined with bevacizumab may be a viable treatment option for patients with PMPM who cannot tolerate traditional chemotherapy. Further studies are needed to evaluate the broader applicability of this combination therapy in PMPM management.

Conclusion

Revise to reflect only the findings of the case report without suggesting further investigation.

Related Resources & Content

  1. The ASCO Post, 2021 -- Neoadjuvant Atezolizumab Under Study in Mesothelioma
  2. The ASCO Post, 2023 -- Phase III Trial Reports Chemoimmunotherapy Is Superior to Chemotherapy Alone in Malignant Pleural Mesothelioma KEY POINTS
  3. Frontiers in Oncology, 2026 -- Case report: Non-surgical triumph in pericardial paraganglioma: durable tumor regression via targeted embolization of coronary collaterals
  4. Clinical Research in Cardiology, 2023 -- Combination of Cadonilimab and Anlotinib Shows Promise in Treating Rare Cardiac Angiosarcoma with Multiple Metastases: A Case Study and Review of Existing Literature
  5. Isolated primary pericardial sarcomatoid mesothelioma: a case report
  6. Isolated primary pericardial sarcomatoid mesothelioma: a case report
  7. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743 - PMC

Original Source(s)

Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

  • by Zijuan Liu, Yating Yan, Caihong Jiang

  • June 16, 2026

Related Content

Who Decides How AI Enters Pathology?

Liron Pantanowitz explains why validation, leadership, and real-world use matter more than performance metrics

Parabilis Sets Biotech IPO Record

The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement

  • June 15, 2026

  • 2 min
Glioma management and outcome in low-middle-income countries: a systematic review